EP4176048
GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
23.9.2021EP published:
11.9.2024EP application number:
21787042.7
EPO information:
European Patent Register
Max expiry date:
22.9.2041
Title in English:
GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCELanguage of the patent:
English
Timeline
Today
23.9.2021EP application
11.9.2024EP Publication
Owner
Name:
CRISPR Therapeutics AGAddress:
Baarerstrasse 14, 6300 Zug, CH
Inventor
Name:
DEQUEANT, Mary-LeeAddress:
Cambridge, Massachusetts 02139, US
Name:
KALAITZIDIS, DemetriosAddress:
Cambridge, Massachusetts 02139, US
Name:
GHONIME, MohammedAddress:
Cambridge, Massachusetts 02139, US
Priority
Number:
202063082357 PDate:
23.9.2020Country:
US
Number:
202063124429 PDate:
11.12.2020Country:
US
Number:
202163225673 PDate:
26.7.2021Country:
US
Classification
Categories:
A61K 39/00, C12N 5/0783, A61K 35/17, A61K 38/00, C12N 15/113, C12N 15/90, A61K 48/00